467 related articles for article (PubMed ID: 22310613)
81. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN
Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
[TBL] [Abstract][Full Text] [Related]
82. Detailed examination of HLA antibody development on renal allograft failure and function.
Zhu L; Lee PC; Everly MJ; Terasaki PI
Clin Transpl; 2008; ():171-87. PubMed ID: 19711514
[TBL] [Abstract][Full Text] [Related]
83. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant?
Gupta A; Iveson V; Varagunam M; Bodger S; Sinnott P; Thuraisingham RC
Transplantation; 2008 Apr; 85(8):1200-4. PubMed ID: 18431242
[TBL] [Abstract][Full Text] [Related]
84. Kidney transplantation in hepatitis C-positive recipients: does type of induction influence outcomes?
Sureshkumar KK; Thai NL; Marcus RJ
Transplant Proc; 2012 Jun; 44(5):1262-4. PubMed ID: 22663997
[TBL] [Abstract][Full Text] [Related]
85. Early Intervention in Living Kidney Transplantation Based on Dynamic Monitoring of Donor Specific Antibodies.
Chen Y; Li LY; Lou XY; Wang H; Zhang L; Zhu YH
Clin Transpl; 2014; ():205-8. PubMed ID: 26281146
[TBL] [Abstract][Full Text] [Related]
86. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
[TBL] [Abstract][Full Text] [Related]
87. Clinical relevance of anti-HLA donor-specific antibodies detected by Luminex assay in the development of rejection after renal transplantation.
Caro-Oleas JL; González-Escribano MF; Gentil-Govantes MÁ; Acevedo MJ; González-Roncero FM; Blanco GB; Núñez-Roldán A
Transplantation; 2012 Aug; 94(4):338-44. PubMed ID: 22814330
[TBL] [Abstract][Full Text] [Related]
88. The Role of HLA Antibodies in HLA Mismatched Allogeneic Hematopoietic Stem Cell Transplantation.
Zhang X; Wang J; Zhou Z; Zhang Y; Liu H; Tong C; Yu C; Lu Y; Zhao Y; Xiong M; Zhou JR; Juan S; Liu DY; Wei Z; Zhang J; Wu T; Lu DP
Clin Transpl; 2014; ():245-50. PubMed ID: 26281152
[TBL] [Abstract][Full Text] [Related]
89. Sensitivity, specificity and clinical relevance of different cross-matching assays in deceased-donor renal transplantation.
Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Hallar M; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N
Transpl Immunol; 2008 Nov; 20(1-2):61-7. PubMed ID: 18929659
[TBL] [Abstract][Full Text] [Related]
90. Kidney transplantation from HLA-incompatible live donors: Efficiency and outcome of 32 patients after desensitisation.
Fernández C; Calvo M; Leite N; López A; Ferreiro T; Ribera R; Seijo R; Alonso Á
Nefrologia; 2017; 37(6):638-645. PubMed ID: 28734583
[TBL] [Abstract][Full Text] [Related]
91. Kidney transplantation using donors over 70 years old: are the criteria for organ allocation too expanded?
Machado S; Figueiredo N; Neves M; Macário F; Alves R; Mota A; Campos M
Transplant Proc; 2012 Oct; 44(8):2289-92. PubMed ID: 23026576
[TBL] [Abstract][Full Text] [Related]
92. Immunological risk assessment: The key to individualized immunosuppression after kidney transplantation.
Pratschke J; Dragun D; Hauser IA; Horn S; Mueller TF; Schemmer P; Thaiss F
Transplant Rev (Orlando); 2016 Apr; 30(2):77-84. PubMed ID: 26965071
[TBL] [Abstract][Full Text] [Related]
93. The clinical significance of human leukocyte antigen antibody development in kidney transplantation.
Lee PC; Chen YL; Chou TC; Wang WM; Wang JD; Hung CJ; Chang SS; Lin YJ; Chan RH
Transplant Proc; 2012 Jan; 44(1):264-6. PubMed ID: 22310628
[TBL] [Abstract][Full Text] [Related]
94. Human leukocyte antigen mismatches associated with increased risk of rejection, graft failure, and death independent of initial immunosuppression in renal transplant recipients.
Lim WH; Chadban SJ; Clayton P; Budgeon CA; Murray K; Campbell SB; Cohney S; Russ GR; McDonald SP
Clin Transplant; 2012; 26(4):E428-37. PubMed ID: 22672477
[TBL] [Abstract][Full Text] [Related]
95. Post-transplant DSA monitoring may predict antibody-mediated rejection in sensitized kidney transplant recipients.
Mohamed MA; Muth B; Vidyasagar V; Foley D; Fernandez L; Hofmann RM; Mezrich J; Pirsch J; Odorico J; d'Alessandro T; Bellingham J; Torrealba J; Kaufman D; Djamali A
Clin Transpl; 2011; ():389-94. PubMed ID: 22755436
[TBL] [Abstract][Full Text] [Related]
96. Prospective Monitoring of Donor-specific Anti-HLA Antibodies After Intestine/Multivisceral Transplantation: Significance of De Novo Antibodies.
Kubal C; Mangus R; Saxena R; Lobashevsky A; Higgins N; Fridell J; Tector AJ
Transplantation; 2015 Aug; 99(8):e49-56. PubMed ID: 25769071
[TBL] [Abstract][Full Text] [Related]
97. Renal transplant allocation criteria, desensitization strategies and immunosuppressive therapy in retransplant renal patients.
Salvadori M; Bertoni E
J Nephrol; 2012; 25(6):890-9. PubMed ID: 22972671
[TBL] [Abstract][Full Text] [Related]
98. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
Everly MJ; Rebellato LM; Haisch CE; Ozawa M; Parker K; Briley KP; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
Transplantation; 2013 Feb; 95(3):410-7. PubMed ID: 23380861
[TBL] [Abstract][Full Text] [Related]
99. The role of therapeutic apheresis in high immunologic risk renal transplantation: a review of current trends.
Sanoff SL; Balogun RA; Lobo PL
Semin Dial; 2012; 25(2):193-200. PubMed ID: 22321316
[TBL] [Abstract][Full Text] [Related]
100. Pre-transplant low level HLA antibody shows a composite poor outcome in long-term outcome of renal transplant recipients.
Tian J; Li D; Alberghini TV; Rewinski M; Guo N; Bow LM
Ren Fail; 2015 Mar; 37(2):198-202. PubMed ID: 25565259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
